A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor.

Slides:

Advertisements

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized.

Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients Natalia Sutiman, BSc, Shao.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004.

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung.

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer Rogerio.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Journal of Thoracic Oncology

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector.

Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II.

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment.

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy Yuh-Min Chen, MD, PhD, Reury-Perng Perng, MD, PhD, Jen-Fu.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non- small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non- small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia.

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly Swan Swan Leong, MD, Chee Keong Toh, MD, Wan Teck Lim, MD, Xu Lin, PhD, Say Beng Tan, PhD, Donald Poon, MD, Miah Hiang Tay, MD, Kian Fong Foo, MD, Juliana Ho, MD, Eng Huat Tan, MD Journal of Thoracic Oncology Volume 2, Issue 3, Pages 230-236 (March 2007) DOI: 10.1097/JTO.0b013e318031d06f Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Quality of Life-Cancer 30 Questionnaire (version 3.0) global health scores by treatment groups. QoL, quality of life; GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, 230-236DOI: (10.1097/JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Quality of Life Questionnaire Lung Cancer–Specific Module scores by treatment group. QoL, quality of life; GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, 230-236DOI: (10.1097/JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Quality of Life Questionnaire Lung Cancer–Specific Module question 3 scores by Eastern Cooperative Oncology Group (ECOG) status. Journal of Thoracic Oncology 2007 2, 230-236DOI: (10.1097/JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Progression-free survival by treatment group. GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, 230-236DOI: (10.1097/JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Overall survival by treatment group. GEM, gemcitabine; VIN, vinorelbine; DOC, docetaxel. Journal of Thoracic Oncology 2007 2, 230-236DOI: (10.1097/JTO.0b013e318031d06f) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions